Home > Insider Trading > Filing (0001209191-14-046415)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1245104	Globeimmune Inc	GBIM	Pharmaceutical Preparations (2834)	841353925

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
816284	Celgene Corp /De/	86 Morris Avenue Summit NJ 07901		No	No	Yes	No
1558852	Celgene International Inc	86 Morris Avenue C/O Celgene Corp Summit NJ 07901		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-07-08	68,832	$0.00	68,832	No	4	C	Direct
Common Stock	Acquisiton	2014-07-08	275,582	$0.00	344,414	No	4	C	Direct
Common Stock	Acquisiton	2014-07-08	56,256	$0.00	400,670	No	4	C	Direct
Common Stock	Acquisiton	2014-07-08	200,000	$10.00	600,670	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2014-07-08	2,160,682	$0.00	68,832	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2014-07-08	8,650,519	$0.00	275,582	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2014-07-08	1,765,888	$0.00	56,256	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Upon closing of the Issuer's initial public offering, each share of Series C Convertible Preferred Stock automatically converted at a ratio of 1-for-31.39 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.
These shares are owned directly by Celgene International Inc. ("Celgene International"), a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Upon closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted at a ratio of 1-for-31.39 into the number of shares of Common Stock shown in column 7 withouth payment of further consideration. The shares had no expiration date.
Upon closing of the Issuer's initial public offering, each share of Series E Convertible Preferred Stock automatically converted at a ration of 1-for-31.39 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date.
These shares are owned directly by Celgene. Celgene International disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.